Investor Kit

Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
05/10/18
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
10/15/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
09/26/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
09/07/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
09/07/183Initial filing by director officer or owner of more than ten percent.3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
09/07/183Initial filing by director officer or owner of more than ten percent.3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
10/11/18New Research Reveals Potency and Quantity of Opioids Prescribed for Postsurgical Pain Poses Danger to Patients, their Families and Friends
Patients prescribed nearly 100 to 200 opioid pills to help manage pain from four common procedures Persistent opioid use spikes among millennial women; Nearly one-in-five millennials report becoming addicted to or dependent on opioids following surgery   PARSIPPANY, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Despite ongoing efforts to end America’s opioid crisis, patients continue to receive large quantities of opioids for postsurgical pain. New research shows that patients received nearly 1... 
Printer Friendly Version
08/08/18Pacira Pharmaceuticals to Present at the 2018 Wedbush Pacgrow Healthcare Conference
PARSIPPANY, N.J., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today reported that it will present at the 2018 Wedbush Pacgrow Healthcare Conference at 9:45 AM ET on Tuesday, August 14, 2018. Live audio of the presentation can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira                                                  ... 
Printer Friendly Version
08/02/18Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results
-- EXPAREL® net product sales of $80.4 million up 15% over prior year second quarter -- -- Full-year EXPAREL net product sales guidance increased to $320 to $325 million -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the second quarter ended June 30, 2018. “The first half of 2018 was marked by tremendous progress as our EXPAREL growth strategy i... 
Printer Friendly Version
07/25/18Pacira to Report Second Quarter 2018 Financial Results on Thursday August 2, 2018
PARSIPPANY, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 2, 2018. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. To participate in the conference call, dial 1-877-845-0779 and provide the passcode 5387259. International callers may dial 1-720-545-0035 and use the same passcode.... 
Printer Friendly Version
07/10/18Pacira Reports Preliminary Net EXPAREL® Sales of $80.4 Million for Second Quarter of 2018
Increase of 15% underscores growing market adoption PARSIPPANY, N.J., July 10, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported preliminary EXPAREL® (bupivacaine liposome injectable suspension) net product sales of $80.4 million for the second quarter of 2018, a 15 percent increase over EXPAREL net product sales of $69.8 million reported in the second quarter of 2017. During the second quarter of 2018, average daily sales grew 11 percent, 16 percent, and 18 p... 
Printer Friendly Version
06/19/18Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China
PARSIPPANY, N.J. and SHANGHAI, China, June 19, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the su... 
Printer Friendly Version
06/15/18Aetna DocFind Directory Now Highlights Providers Offering Opioid Alternatives, Including EXPAREL®
DocFind update helps Aetna members connect with surgeons trained in managing postsurgical pain using non-opioid medications PARSIPPANY, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. today announced further collaboration with Aetna, one of the nation’s leading diversified health care benefits companies. Aetna has updated its online provider directory, DocFind, to help members easily identify surgeons who are committed to offering opioid alternatives, including EXPAREL® (... 
Printer Friendly Version
06/13/18MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS™) Collaborative to Minimize Opioid Use
FORT LAUDERDALE, Fla., June 13, 2018 – MEDNAX, Inc. (NYSE:MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to address the ongoing use of opioids during and after cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim throu... 
Printer Friendly Version
05/31/18Pacira Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
PARSIPPANY, N.J., May 31, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported that Dave Stack, chairman and chief executive officer, will present at the Jefferies 2018 Healthcare Conference at 9:30 AM ET on Tuesday, June 5, 2018. Live audio of the presentation can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira Pharm... 
Printer Friendly Version
05/03/18Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results
-- EXPAREL® net product sales of $74.0 million up 9% over prior year first quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the first quarter ended March 31, 2018. “2018 is off to a terrific start with EXPAREL daily sales volumes accelerating from 6 percent in January to 15 percent in March, as well as a recently expanded label that now inclu... 
Printer Friendly Version
>> Access Older Press Releases